SAN DIEGO, Feb. 21, 2014 /PRNewswire/ -- Organovo Holdings,
Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology
company focused on delivering breakthrough 3D bioprinting
technology, announced today that it has been invited to participate
at the Citi 2014 Global Healthcare Conference, which will be held
in New York February 24 – 26, 2014.
Organovo's Chief Technical Officer and Executive Vice
President of Research and Development Dr. Sharon Presnell,
will be participating in a panel discussion on 3D Printing and Its
Role in Medical Devices on Wednesday,
February 26, 2014, from 1:00 – 1:45
PM. The conference will be held at the Hilton New York
Hotel – New York.
About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional
human tissues for medical research and therapeutic applications.
The Company is collaborating with pharmaceutical and academic
partners to develop human biological disease models in three
dimensions. These 3D human tissues have the potential to accelerate
the drug discovery process, enabling treatments to be developed
faster and at lower cost. In addition to numerous scientific
publications, the Company's technology has been featured
in The Wall Street Journal, Time Magazine, The Economist,
and numerous others. Organovo is changing the shape of
medical research and practice. Learn more
at www.organovo.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that
term is defined in the Private Securities Litigation Reform Act of
1995. Any forward-looking statements contained herein are based on
current expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results
to differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company's
ability to develop, market and sell products based on its
technology; the expected benefits and efficacy of the Company's
products and technology; and the Company's business, research,
product development, regulatory approval, marketing and
distribution plans and strategies. These and other factors are
identified and described in more detail in our filings with
the SEC, including our prospectus supplement filed with
the SEC on August 2, 2013 and our transition report
on Form 10-KT filed with the SEC on May 24, 2013 as well as our other filings
with the Securities and Exchange Commission. You should not
place undue reliance on these forward-looking statements, which
speak only as of the date that they were made. These cautionary
statements should be considered with any written or oral
forward-looking statements that we may issue in the future. Except
as required by applicable law, including the securities laws
of the United States, we do
not intend to update any of the forward-looking statements to
conform these statements to reflect actual results, later events or
circumstances or to reflect the occurrence of unanticipated
events.
SOURCE Organovo Holdings, Inc.